1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results

BACKGROUND: Lenacapavir (LEN), a potent first-in-class inhibitor of HIV-1 capsid function, is in development as a long-acting agent for treatment and prevention of HIV-1. METHODS: CAPELLA is an ongoing, phase 2/3 study in heavily treatment-experienced (HTE) people with HIV-1 (PWH) with multidrug-res...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogbuagu, Onyema, Segal-Maurer, Sorana, Ratanasuwan, Winai, Trottier, Benoit, Brunetta, Jason, Shirasaka, Takuma, Koenig, Ellen L, Wang, Hui, Margot, Nicolas A, Dvory-Sobol, Hadas, Rhee, Martin S, Baeten, Jared, Molina, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752342/
http://dx.doi.org/10.1093/ofid/ofac492.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752342/
http://dx.doi.org/10.1093/ofid/ofac492.108

Ejemplares similares